FDA sets cross-labelling meeting date
This article was originally published in Clinica
Executive Summary
The FDA has finally scheduled its promised public meeting on cross labelling - when a company seeks to develop or market a device or some other product type that would be labelled for use with an already approved prescription drug or some other product type.